Once-Weekly Semaglutide in Adolescents with Obesity.

Daniel WeghuberTimothy BarrettMargarita Barrientos-PérezInge GiesDan HesseOle K JeppesenAaron S KellyLucy D MastrandreaRasmus SørrigSilva A Arslaniannull null

Published in: The New England journal of medicine (2022)

Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).

Keyphrases

weight loss
metabolic syndrome
weight gain
insulin resistance
randomized controlled trial
physical activity
type diabetes
high fat diet induced
body mass index
young adults
cardiovascular disease
skeletal muscle
replacement therapy
smoking cessation